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Abstract    
Background 
Irritable Bowel Syndrome (IBS) patients may experience post-prandial symptom 
exacerbation. Nutrients stimulate intestinal release of glucagon-like peptide 1 (GLP-1), an 
incretin hormone with known gastrointestinal effects. However, prior to the post-prandial rise 
in GLP-1, levels of the hunger hormone, ghrelin, peak. The aims of this study were to 
determine if ghrelin sensitizes colonic intrinsic and extrinsic neurons to the stimulatory 
actions of a GLP-1 receptor agonist, and if this differs in a rat model of IBS.  
Methods 
Calcium imaging of enteric neurons were compared between Sprague Dawley and Wistar 
Kyoto rats. Colonic contractile activity and vagal nerve recordings were also compared 
between strains.  
Key Results  
Circulating GLP-1 concentrations differ between IBS subtypes. Mechanistically, we have 
provided evidence that calcium responses evoked by exendin-4, a GLP-1 receptor agonist are 
potentiated by a ghrelin receptor (GHSR-1) agonist, in both submucosal and myenteric 
neurons. Although basal patterns of colonic contractility varied between Sprague Dawley and 
Wister Kyoto rats, the capacity of exendin-4 to alter smooth muscle function was modified by 
a GHSR-1 agonist in both strains. Gut-brain signaling via GLP-1 mediated activation of vagal 
afferents was also potentiated by the GHSR-1 agonist.  
Conclusions & Inferences 
These findings support a temporal interaction between ghrelin and GLP-1, where the pre-
prandial peak in ghrelin may temporarily sensitize colonic intrinsic and extrinsic neurons to 
the neurostimulatory actions of GLP-1. Whilst the sensitizing effects of the GHSR-1 agonist 
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 Many patients with Irritable Bowel Syndrome report exacerbation of symptoms 
following food intake, however the mechanisms underlying this phenomenon are 
unclear. 
 Brief exposure to the ghrelin receptor agonist potentiated neuronal activation in 
colonic enteric neurons and vagal afferents by a GLP-1 mimetic. Colonic contractile 
activity was differentially modified in an animal model of Irritable Bowel Syndrome. 
 In a rat model of gastrointestinal dysfunction, sensitization of colonic intrinsic and 








Ghrelin, a stomach-derived orexigenic hormone plays a key role in whole-body energy 
metabolism and is often termed the ‘hunger hormone’. However, in addition to regulating this 
basic survival instinct, ghrelin also modifies gut motility and visceral pain sensitivity through 
its actions on intrinsic myenteric neurons and extrinsic vagal and pelvic nerves, respectively1. 
Interestingly, ghrelin-mediated modulation of myenteric neuronal activity is dependent on 
fasting state. Larger calcium responses are generated in the myenteric neurons of fasted 
guinea pigs as compared to re-fed animals, results which indicate the importance of neuro-
endocrine regulation of satiety and satiation2. Glucagon-like peptide-1 (GLP-1) is a gut-
derived hormone important in satiety. Released from intestinal L-cells in response to the 
arrival of nutrients in the small intestinal lumen3, this incretin hormone enhances glucose-
stimulated insulin biosynthesis and secretion. In the gastrointestinal (GI) tract the effects of 
GLP-1 vary with location. Gastric emptying, the migrating motor complex and small 
intestinal secretion are inhibited by GLP-14, in contrast to its effects in the colon, where a 
vagally-mediated increase in transit resulted from central administration of GLP-15. GLP-1-
mediated changes in motility have been observed in both healthy controls and in patients with 
Irritable Bowel Syndrome (IBS)6-8. 
 
IBS is a common9, heterogeneous functional bowel disorder, characterized by abdominal pain 
and episodes of either diarrhea, constipation, or both10. Miscommunication in the brain-gut 
axis is thought to underlie the pathophysiology, with alterations in neuroendocrine signaling 
being implicated11. Clinical interventions in IBS patients demonstrated that a GLP-1 mimetic 
had anti-spasmodic and pain-relieving properties12 and may have therapeutic efficacy in 
constipation-predominant IBS (IBS-C)13. A prevalent feature of the disorder is post-prandial 
exacerbation of symptoms14-16, making hunger- and satiety-related hormones an area of 




Ghrelin can enhance the post-prandial nutrient-evoked increase in GLP-1 secretion17 and has 
been proposed as a potential incretin enhancer therapy18. This is consistent with the temporal 
profile of circulating ghrelin, which peaks with hunger prior to a meal19, and GLP-1, which 
peaks 10-15 minutes following a meal20. However, GLP-1 receptor (GLP-1R)-expressing 
neurons are found in both neuronal plexi of the enteric nervous system throughout the GI 
tract21, including the colon.  
 
Vagal and spinal visceral afferents provide a constant stream of interoceptive information to 
the central nervous system. Unlike healthy controls, IBS patients appear to be conscious of 
these sensory inputs22, which is interpreted as abdominal discomfort or pain. The vagus nerve 
has been linked to activation of the hypothalamic-pituitary stress axis, and modification of 
gut-originating pain signaling, which, in turn, leads to altered gut function23. The entire GI 
tract in rats is innervated by the vagus24, and the dorsal motor nucleus of the vagus25 and 
vagal afferents are sensitive to GLP-126. We hypothesize that ghrelin may sensitize gut 
intrinsic and extrinsic neurons to the stimulatory effects of GLP-1 and thereby alter GI 
function. The aims of the study were to determine the importance of GLP-1 and ghrelin in the 






Materials and Methods 
Ethical approval 
All experiments were in full accordance with the European Community Council Directive 
(86/609/EEC) and the local University College Cork animal ethical committee (#2011/015). 
Rats were sacrificed by CO2 overdose and exsanguination. 
The protocol for collecting biopsies from the transverse and distal colon with matched serum 
samples from IBS patients and healthy control volunteers was approved by the University 
College Cork Clinical Research Ethics Committee (ECM 4(r) 01/03/16) and was carried out 
in the Mater Private Hospital, Cork, Ireland. Informed consent was obtained from all 
participants. 
 
Animals and Tissue collecting 
Anxiety- and depression-like behaviors, including stress-induced defecation and time spent in 
the aversive, exposed inner zone of the open-field arena and behavior in the forced swim test 
are not reported to differ between male and female Sprague Dawley (SD) and Wistar Kyoto 
(WKY) rats27. Moreover, both male28 and female29 WKY rats exhibit lower pain threshold to 
CRD as compared to SD rats. Given the lack of sex difference and to avoid the cyclical 
hormonal changes, 8-12 week old male SD and WKY rats, purchased from Envigo, 
Derbyshire, UK, were selected for this study. Rodents were group-housed 5 per cage and 
maintained on a 12/12 hour light -dark cycle (08.00-20.00) with a room temperature of 
22±1oC. Animals were permitted at least a week to acclimatize to their new environment 
prior to experimentation. Food and water were available ad libitum and rats were not fasted 
prior to tissue collection. In comparison to SD rats, WKY rats exhibit increased sensitivity to 
stress30-32. In several studies where SD rats were used as comparators, WKY rats exhibited a 
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high anxiety phenotype, visceral hypersensitivity and increased stress-related defecation. This 
model of brain-gut axis dysfunction has been validated as a rodent model of IBS32-35. 
 
A section of distal colon was excised from each rat and stored in cold Krebs buffered saline 
containing in mmolL-1: 117 NaCl, 4.8 KCl, 2.5 CaCl2, 1.2 MgCl2, 25 NaHCO3, 1.2 NaH2PO4 
and 11 D-glucose (pH 7.4). For calcium imaging and immunofluorescence studies, the 
mucosal layer was removed to expose the submucosal plexus (SMP). To expose myenteric 
neurons, the circular muscle layers were peeled away using forceps leaving a longitudinal 
muscle myenteric plexus (LMMP) preparation. Sections of distal colon stripped of the 
mucosa were used for gut bath studies. The dissection technique used for the colon-vagal 
nerve tissue preparation is described in detail below. 
 
Human plasma and colon biopsy collection 
Patients attending the General Surgery Clinic at the Mater Private Hospital, Cork, Ireland 
were recruited for the study. Patients aged between 18-65 years of age and able to provide 
written informed consent were enrolled. Inclusion criteria for IBS patients included 
confirmed clinical diagnosis of IBS that satisfies the Rome III criteria. Biopsies from age and 
weight-matched healthy controls were taken from patients undergoing routine colonoscopies 
that were good health and negative for bowel disease. Exclusion criteria for participation 
included acute or chronic co-existing illness, recent unexplained bleeding or prior GI surgery 
(apart from hernia repair and appendectomy), psychiatric disease, immunodeficiency, 
bleeding disorder, coagulopathy, a malignant disease or any concomitant end-stage organ 
disease. Subjects were also excluded if they were taking any experimental drugs or if the 
subject had taken part in an experimental trial less than 30 days prior to this study. Mucosal 
biopsies from the transverse and distal colons were taken from fasting patients at the same 
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time as obtaining a matched serum sample. Dipeptidyl peptidase-IV was added to the serum 
samples to inhibit GLP-1 degradation. Samples were assigned a study number, with the key 
held by the treating surgeon, so as to preserve patient confidentiality in accordance with the 
study protocol. The secretory products from biopsies incubated in Dubellco’s Modified Eagle 
Medium (Sigma Aldrich, UK, overnight, 37oC) were used to measure local tissue 
concentration of GLP-1 and ghrelin. Mucosal biopsies were subsequently fixed overnight in 
4% paraformaldehyde, cryoprotected in 30% sucrose and stored at -80°C for later 
immunofluorescent staining.   
 
Mesoscale Discovery Biomarker Assay 
An immunoassay (MesoScale Discovery U-PLEX customized multiplex assay kit I, 
MesoScale Discovery, Gaithersburg, MD, USA) was carried out to determine the GLP-1 and 
ghrelin concentration in plasma samples and biopsy supernatants from 6 healthy, 6 IBS-C and 
6 IBS-D patients. The assay was run in triplicate and an electrochemiluminescent detection 
method was used to measure protein levels in the samples. The plates were read using 
MesoScale Discovery plate-reader (MESO QuickPlex SQ 120). A calibration curve was 




For calcium imaging studies, a LMMP or SMP tissue preparation was pinned out in Sylgard 
(Sylgard 184 silicone elastomer kit, WPI, Sarasota FL, USA)-lined petri dishes superfused 
with carbogen-bubbled Krebs saline solution with 1μM nifedipine to inhibit smooth muscle 
contractions. The tissue was loaded with either Fluo 4 (8μM, 1 hr, Thermo Fisher Scientific, 
Waltham, MA, USA) or Fura-2AM (Thermo Fisher Scientific 7μM, 1 hr) in the dark and 
9 
 
washed out prior to recording. Cytosolic changes in intracellular calcium ([Ca2+]i) were 
recorded from neuronal cell bodies loaded with Fluo-4 using WinFluor fluorescence image 
capture and analysis program (John Dempster, University of Strathclyde, Scotland) or from 
neurons loaded with Fura-2AM using Cell R software (Olympus Soft imaging solutions, 
1986-2009). Images were captured at 2Hz using a Cairn optoscope 1200 (Cairn Research, 
Kent, UK) or a Xenon/Mercury arc burner (Olympus, Melville, NY, US), a charge-coupled 
device digital camera (Hamamatsu ORCA-ER, Hamamatsu Photonics, Hertfordshire, UK) 
and a 40x water-immersion objective on a fixed stage upright microscope (BX51WI, 
Olympus, South-End-on-Sea, UK).  
 
Ganglionic neurons were identified based on morphology and responsivity to brief exposure 
to 75mM KCl, which was added at the end of each experiment. Neurons were considered to 
be responders if fluorescence increased (in 150 seconds from the point of the initiation of the 
calcium response) by more than two standard deviations from baseline noise values for each 
neuron. The baseline values were calculated as the average ratio during the 150 seconds 
preceding the stimulus and compared to the peak amplitude of response (150 seconds). A 
perfusion system continuously superfused the colonic tissue with carbogen-bubbled Krebs-
buffered saline. The tissue was incubated with pharmacological reagents added to the 
superfusate. 
 
Immunofluorescence and confocal microscopy 
Human distal colonic biopsies, fixed in 4% paraformaldehyde (4oC, overnight), were cryo-
sectioned (10µm in thickness, Leica Biosystems, Wetzler, Germany) and mounted on glass 
slides (VWR, Dublin 15, Ireland). Mucosal biopsies were permeabilized with 0.1% Triton X-
100 and blocked with 1% donkey serum (Sigma Aldrich, UK) and immunolabelled with 
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rabbit polyclonal anti-GLP-1 antibody36 (1:250, overnight 4oC, Abcam, Cambridge, UK). 
FITC-anti rabbit fluorophore (green staining, 1:250, 2 hrs, 37oC, Jackson Immunoresearch, 
PA, US) was used to visualize GLP-1 expression. Tissue sections were mounted using Dako-
fluorescent mounting medium containing DAPI (Agilent Pathology Solutions Santa Clara, 
California, USA) and a coverslip placed over all tissue. Images were captured using a FVl0i-
Olympus-confocal microscope with Fluoview software (FV10i-SW, Olympus Europe, 
Hamburg, Germany). No non-specific fluorescence was detected in control experiments using 
a GLP-1 binding peptide prior to tissue exposure as compared to a positive control. Controls 
for the secondary fluorophore (tissues were incubated with primary antibody in the absence 
of secondary antibody or the secondary antibody was applied alone) similarly showed no 
non-specific immunofluorescent staining.  
 
Extracellular recording from colonic vagal afferents  
This dissection has been described previously in detail37. In brief, a vertical abdominal 
incision was made below the sternum to expose the intestine with intact peripheral nerves. 
The esophagus with intact posterior vagus and its branches were excised. An ex vivo 
preparation of the distal colon with intact inferior and superior mesenteric and coeliac ganglia 
and the vagus nerve was excised from the abdominal cavity of SD or WKY rats. Vagal nerve 
activity was recorded superior to the stomach near the attached portion of the esophagus. The 
nerve-gut recording rig consisted of two Sylgard-lined Perspex chambers. The colon chamber 
(2.5cm x 10cm) was separated from the adjacent nerve chamber (1.5cm x 10cm) by a 2mm 
barrier. Both chambers were superfused with 5% CO2/95 % O2 bubbled Krebs saline 
comprised of (in mmolL-1): NaCl, 117; KCl, 4.8; CaCl2, 2.5; MgCl2, 1.2; NaHCO3, 25; 
NaH2PO4, 1.2 and D-glucose maintained at 37
oC. The colonic tissue was opened at the 
mesenteric border and pinned out, mucosal side up. The serosal side of the tissue was 
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continuously irrigated with perforated plastic tubing embedded in the Sylgard. To expose 
myenteric neurons, the mucosal and submucosal layers were removed and the circular muscle 
fibers were peeled away using fine dissection forceps. To prevent damaging the nerves, glass 
rods were used to thread the nerves and ganglia through to the nerve-recording chamber, 
which was sealed with petroleum jelly. The vagal nerve bundles were placed on platinum 
bipolar recording electrodes (WPI, Sarasota, FL, USA) attached to a Power lab (AD 
Instruments, Oxford, UK). The nerve activity was viewed and recorded with Chart 7 (AD 
Instruments, Oxford, UK). High- and low-pass filters were set at 0.2 and 2kHz, respectively 
and the signal was filtered to exclude mains fluctuation. Data was analyzed in GraphPad 
Prism for Windows (version 5) and presented as area under the curve (AUC). 
 
Gut Bath electrophysiology 
Sections of distal colon were opened along the mesenteric border and the mucosa was 
removed. Tissue was either suspended transversely to measure circular muscle contractility or 
longitudinally to measure longitudinal muscle contractile activity. The colonic sections were 
suspended from a tension transducer under 1g of tension in a water-jacketed tissue bath, 
maintained at 37oC in Krebs-buffered saline and allowed to equilibrate for up to an hour. 
Colonic sections were stimulated with the cholinergic agonist, carbachol (1μM, Sigma 
Aldrich, 5 min) at the beginning and at the end of each protocol to stimulate a maximal 
contractile response and ensure no decline in muscle responsiveness was occurring over time. 
Baseline contractile activity was recorded for 10 minutes prior to addition of reagents such as 
the GLP-1 mimetic, exendin-4 (10μM, Abcam Laboratories, Cambridge, UK) and the ghrelin 
receptor agonist, Ibutamoren mesylate (MK-667, 1μM, Sigma Aldrich, UK). Contractile 
changes in isolated muscle strips were recorded via a mechanical transducer and Powerlab 
system and LabChart7 (all AD instruments Inc, Colorado Springs, CO, USA). LabChart7 was 
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used to measure the area under the curve (AUC), which was used to incorporate both the 
amplitude and frequency of colonic contractions. The rectified trace was calculated by 
computing the integral of the raw data. 
 
 Statistical Analyses  
Data was analyzed using GraphPad prism for windows (version 7). Data were plotted as box 
and whisker plots with 95% confidence intervals. Data were compared using paired two-
tailed Student’s or paired t-tests, as appropriate or One-way or repeated measures ANOVA 





Circulating levels of GLP-1 differ between IBS patient subtypes.  
Circulating levels of GLP-1 and ghrelin were compared between fasting healthy controls 
(HCs), IBS-C and IBS-D patients (n=6 samples per group). Plasma GLP-1 was similar in 
HCs and IBS-C patients (one-way ANOVA, F(2,14)=1.51, p=0.25) but depressed in IBS-D 
patients (p=0.043, figure 1A(i)). Plasma ghrelin did not differ between fasting HCs, IBS-D 
and IBS-C patients (one-way ANOVA, F(2,14)=0.927, p=0.42, figure 1A(ii)). Tissue 
secretion of GLP-1 from colonic biopsies was higher than plasma levels and, increased in 
IBS-C supernatants, as compared to HCs (one-way ANOVA, F(2,11)=5.81, p=0.019), with 
no change in secretion from IBS-D samples (figure 1A(iii), p=0.8). Ghrelin-secreting cells 
are not thought to be found in the colon, so it was unsurprising that ghrelin was undetectable 
in biopsy supernatants.  
 
To determine if a change in the density of colonic L-cells accounted for altered colonic 
secretion of GLP-1, the numbers of L-cells as a fraction of total DAPI-labelled mucosal cells 
in a given field were compared. In HC biopsies, 3.8% of epithelial cells were identified as 
GLP-1-expressing L-cells, 4.8% of cells in IBS-C biopsies and 3% of cells in the IBS-D 
cohort expressed GLP-1. Although this pattern is consistent with increased secretion of GLP-
1 in IBS-C biopsies (figure 1A(iii)), these differences were not significant (n= 6-10 sections 
per biopsy, n=4 biopsies per group, one-way ANOVA, F(2,23)=1.76, p=0.195, figure 1B). 
 
GLP-1 and ghrelin contribute to the neurostimulatory action of IBS plasma on 
submucosal neurons. 
Previous studies from our lab demonstrated that soluble mediators present in plasma from 
IBS patients but not healthy comparators evoked robust increases in [Ca2+]i in enteric neurons 
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from SD distal colons38,39. Due to the innate variability of individual plasma samples, a 
standard preparation of pooled plasma samples from healthy (n = 6) and IBS (n=6 pooled 
samples from IBS-D, IBS-C and IBS-A) was used to standardize calcium responses and 
facilitate investigation of the potential contribution of circulating GLP-1 and/or ghrelin in the 
neurostimulatory effects of IBS plasma on SD and WKY submucosal neurons. IBS plasma 
was diluted 1:250 in Krebs saline and perfused onto the tissue for 3 minutes. Consistent with 
our previous studies38,39, soluble mediators within the plasma stimulated a robust increase in 
[Ca2+]i in submucosal neurons in both SD (n=41 neurons from 3 rats, figure 2A) and WKY 
(n=28 neurons from 4 rats, figure 2B) rats. Similar proportions of total SD (59%) and WKY 
(64%, Fisher’s exact test, p=0.56) rat submucosal neurons responding to 75mM KCl were 
activated by IBS plasma, suggesting that neurons in both rat strains were equally sensitive to 
the stimulatory factors in IBS plasma.  
 
Although we have already determined that stress and immune factors contribute to the 
stimulatory effect of IBS plasma38,39, the GLP-1R antagonist, exendin (9-39) (Ex(9-39), 
10µM, 10min) and the ghrelin receptor antagonist, YIL781 (10nM, 10min) were utilized to 
determine if either of these gut hormones contributed to the neurostimulatory effect. In SD 
SMP tissue, IBS plasma–evoked calcium responses were reduced by Ex(9-39) (n=20 neurons 
from 3 rats, one-way ANOVA, F(2,75)=6.69, p=0.003), whereas the GHSR-1 antagonist had 
no effect on IBS plasma-evoked responses (n=17 neurons from 3 rats, p=0.317, figure 2A). In 
WKY submucosal neurons, the IBS plasma-evoked calcium response was similarly 
attenuated by Ex(9-39) (one-way ANOVA, F(2,39)=13.39, p<0.001), but in contrast to its 
lack of effect in SD tissue, YIL781 attenuated the IBS plasma-induced calcium response in 




GLP-1 contributes to the neurostimulatory action of IBS plasma on myenteric neurons. 
The neurostimulatory effects of IBS plasma were assessed in the myenteric neurons of SD 
and WKY distal colons. Pooled IBS plasma evoked a robust increase in [Ca2+]i in both SD 
(n=32 neurons from 3 rats, figure 2C) and WKY (n=19 neurons from 3 rats, figure 2D) 
myenteric neurons. The percentage of myenteric neurons responding to IBS plasma (71% SD 
vs 69% WKY, Fisher’s exact test: p=0.878) was similar between rat strains. To determine if 
GLP-1 and ghrelin may represent neurostimulatory soluble mediators present in IBS plasma, 
Ex(3-39) and YIL781 were applied to LMMP tissue prepared from each rat strain. In SD 
tissue, Ex(3-39) inhibited the response evoked by IBS plasma (n=14 neurons from 3 rats, 
one-way ANOVA, F(2,61)=10.74, p<0.001) whereas YIL781 had no effect (n=18 neurons 
from 3 rats, p=0.957, figure 2C). In WKY LMMP tissue, the GLP-1R antagonist similarly 
attenuated the IBS plasma-evoked response (n=18 neurons from 3 rats, one-way ANOVA, 
F(2,51)=9.36, p<0.001), whereas the ghrelin receptor antagonist had no effect (n=15 neurons 
from 3 rats, p=0.59, figure 2D). 
 
MK-667 sensitizes colonic submucosal neurons to exendin-4. 
We have previously noted differences between SD and WKY enteric neurons in their 
sensitivity to neuromodulatory molecules40. Calcium imaging of submucosal neurons 
demonstrated that the GLP-1R agonist, exendin-4 (Ex-4, 10µM, 3 min) evoked a small, short-
lived increase in [Ca2+]i in SD rats that was reproducible, with no difference between the first 
and second application (n=10 neurons from three rats, paired t-test: p=0.489, figure 3A). Ex-4 
evoked a calcium response in both SD (n=18 neurons from 3 rats, figure 3B) and WKY rats 
(n=26 neurons from 3 rats, figure 3C). The ghrelin receptor agonist, MK-667 (1µM, 3 min) 
evoked an increase in [Ca2+]i, which was similarly short-lived in both strains. No strain 
difference was detected in the amplitude of response for Ex-4 (p=0.898) or MK-667 
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(p=0.08). However, re-application of Ex-4, 10 minutes after the brief exposure to MK-667, 
evoked an enhanced calcium response both in SD (repeated measures ANOVA, 
F(2,44)=9.19, p=0.005, figure 3B) and WKY (repeated measures ANOVA, F(2, 25)=109.8, 
p<0.001, figure 3C) rats. Sensitization of neurons by the GHSR-1 agonist appears to be a 
short-lived phenomenon as 30 minutes after exposure to MK-667, the calcium response 
evoked by Ex-4 in SD submucosal neurons (0.885 ±0.83) was no longer potentiated as 
compared to the control response (1.217 ± 0.86, n=27 neurons from 3 rats, paired t-test: 
p=0.167). The potentiated calcium response did not differ between SD and WKY strains (t-
test: p=0.15).   
 
Potentiation of an exendin-4 evoked calcium response in colonic myenteric neurons by 
MK-667 is larger in Wistar Kyoto rats.  
To determine if the ghrelin agonist similarly sensitized myenteric neurons to the 
neurostimulatory actions of the GLP-1R agonist, Ex-4 (10µM, 3 min) was applied to colonic 
myenteric neurons. An increase in [Ca2+]i was evoked in SD rats, which was reproducible 
upon re-application, with no significant difference between the first and second application 
(n=25, paired t-test: p=0.452, figure 4A). Both Ex-4 and MK-667 evoked calcium responses 
in SD (n=14 neurons from 3 rats, figure 4B) and WKY (n=37 neurons from 3 rats, figure 4C) 
rats. No strain difference in the amplitude of response was detected for Ex-4 (p=0.39). The 
amplitude of response to MK-667, however was larger in WKY rats (p=0.05). Ex-4 applied 
post-exposure to MK-667 resulted in an enhanced calcium response, such that the amplitude 
was significantly larger than the control Ex-4 response in SD (repeated measures ANOVA, 
F(2,13)=8.9, p=0.0023, figure 4B) and in WKY (repeated measures ANOVA, F(2, 
36)=39.13, p<0.001, figure 4C) rats. Moreover, between strains, the potentiated Ex-4 




MK-667 potentiates Ex-4-evoked smooth muscle colonic contractile activity. 
To assess if the potentiation of Ex-4-evoked excitatory activity in myenteric neurons had a 
functional impact on colonic smooth muscle activity, colonic tissue was suspended in gut 
baths in the circular and longitudinal orientations. The cholinergic agonist, carbachol (1µM) 
was applied to the tissue at the beginning and the end of the experiment to evoke a maximal 
response. No run-down in response was detected in either circular (n=6, t-test, p=0.29) or 
longitudinal muscle (n=6, p=0.78). Baseline colonic circular smooth muscle contractions are 
regular in SD rats, with reasonably consistent amplitude and frequency (figure 5A). The 
pattern of circular muscle contractile activity in WKY rats appears more erratic (figure 5B) 
and the amplitude of contractions was reduced (p=0.01, t-test). Longitudinal muscle 
contractile activity in SD rats (figure 5C) is also less erratic than the pattern of activity in the 
WKY rat (figure 5D), which is also of lower amplitude (p=0.009, t-test). However, no 
differences in the frequency of contractions was detected between strains in either circular 
(p=0.427) or longitudinal muscle (p=0.467). As a combined measure of amplitude and 
duration of contractions above baseline, area under the curve (AUC) was compared between 
strains in remaining experiments.  
 
In SD circular muscle, Ex-4 (10µM, 10min) modified the pattern of contraction (n=6, figure 
5A), a response that was reproducible upon repeated application. The response was 
attenuated in the presence of the neurotoxin, tetrodotoxin (100nM, n=5, p=0.025), indicating 
that the action of Ex-4 is primarily neurally-regulated. However, the post-MK-667 (1µM, 
20min) response evoked by Ex-4 was potentiated (repeated measures ANOVA, F(2, 
5)=5.576, p=0.024, figure 5A) with evidence of increased amplitude and frequency of 
contractions, and a notable increase in colonic tone. In WKY circular muscle, Ex-4 
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suppressed the aberrant activity noted at baseline (n=6, figure 5B). The post-MK-667 
application of Ex-4 stimulated increased colonic tone and circular contractile activity 
(repeated measures ANOVA, F(2, 5)=5.2, p=0.028). Despite differences in baseline 
contractile activity, the potentiated response did not differ between strains (t-test, p=0.73). 
 
In SD colonic tissue suspended to record longitudinal muscle activity, the amplitude of 
colonic contractions was suppressed by Ex-4 (n=6, figure 5C) with a decrease in muscle tone. 
However, the effect of Ex-4 was not attenuated significantly by tetrodotoxin (n=5, p=0.166). 
After exposure to MK-667, Ex-4 evoked an increase in colonic tone and more contractile 
activity (repeated measures ANOVA, F(2, 4)=5.27, p=0.035, figure 5C), although the 
synchronicity of the response was lost. In WKY rat colons, Ex-4 suppressed tonic 
longitudinal muscle contractile activity, but the post-MK-667 response evoked by Ex-4 was 
potentiated (repeated measures ANOVA, F(2, 5)=4.32, p=0.044, figure 5D), with a large 
increase in tone and loss of synchronous contractions. The potentiated response in 
longitudinal muscle contractile activity did not differ between strains (n=5, t-test, p=0.413). 
While MK-667 appears to sensitize the colon of both rat strains to the actions of the GLP-1R 
agonist, the patterns of baseline contractile activity vary considerably between SD and WKY 
rats. 
 
Potentiation of Exendin-4 evoked vagal nerve firing by MK-667. 
To determine if the GHSR-1 agonist can sensitize afferent nerve signaling to Ex-4, 
extracellular recordings of colonic vagal nerve fibers were undertaken. In an isolated 
chamber, vagal nerve activity was recorded in response to stimulation of a colonic LMMP 
tissue preparation. Application of Ex-4 (10µM, 10 min) to SD distal colon LMMP stimulated 
a rapid but short-lived increase in vagal nerve firing (n=6 rats, figure 6A). Similarly, Ex-4-
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evoked increase in compound vagal nerve activity in WKY rats (n=6 rats, figure 6B). 
Exposure to the GHSR-1 agonist, MK-667 also evoked a similar afferent nerve response in 
both strains, however, re-application of Ex-4 post-MK-667 resulted in a significantly larger 
increase in vagal firing than the control Ex-4. This potentiation was evident in both SD 
(repeated measures ANOVA, F(2,5)=17.6, p=0.033, figure 6A) and WKY (repeated 
measures ANOVA, F(2,5)=13.05, p=0.027, figure 6B) rats and did not significantly differ 
between strains (t-test: p=0.073). The duration of the response was over twice as long in 
WKY rats as compared to SD rats (SD: 1.46 ±0.61 min, WKY: 3.68 ±0.84 min) although it 
didn’t quite reach statistical significance (t-test: p=0.058). Repeated application of Ex-4 in the 
absence of MK-667 did not result in an enhanced neural response (3.22 ±0.55 vs 3.61 ±0.74, 







In many IBS patients, ingestion of a meal leads to exacerbation of symptoms, including 
abdominal bloating and pain, and diarrhea14-16. The cellular mechanisms underlying this acute 
exacerbation of symptoms is likely to involve both endocrine and afferent nerve signaling. In 
our study, we have used the stress-sensitive WKY rat, which exhibits visceral pain 
hypersensitivity30,34 and increased stress-related defecation32 to determine if endocrine-
mediated modification of GI function differs in an animal model of bowel dysfunction. We 
investigated if ghrelin, which peaks prior to meal ingestion, sensitized colonic intrinsic and 
extrinsic neurons to the neurostimulatory actions of GLP-1. Our findings indicate that the 
ghrelin receptor agonist, MK-667, sensitizes colonic enteric neurons to the neurostimulatory 
effects of a GLP-1R agonist, Ex-4 in both SD and WKY rats. However, despite similar 
neuronal responses, differences between the strains became apparent when colonic function 
was examined. Under basal conditions, WKY rats exhibited aberrant colonic contractile 
activity. Ex-4 suppressed contractile activity in both SD and WKY strains, but this response 
was altered by exposure to MK-667. However, the underlying patterns of contractile activity 
were maintained in WKY rats. In separate experiments, we found that vagal nerve activity, 
which provide the CNS with interoceptive information from the viscera, were stimulated by 
application of Ex-4 to myenteric neurons of the distal colon. Exposure to the GHSR-1 
agonist, potentiated this response. The finding that circulating GLP-1 was altered in human 
IBS-D patients suggested that our mechanistic findings in the rat model may be translatable 
to the human functional bowel disorder.  
 
Ghrelin is primarily secreted by gastric epithelial cells thus it was unsurprising that no ghrelin 
was detected in secretions from colonic biopsies. Nonetheless, acetylated ghrelin, the 
endogenous ligand for GHSR-1, has a reasonably long half-life of ~10 minutes41 and can 
21 
 
activate colonic enteric neurons42. Indeed, MK-667 stimulated a short-lived increase in 
[Ca2+]i in submucosal and myenteric neurons prepared from rat colons. We previously 
demonstrated that IBS plasma, which contains neurostimulatory soluble mediators, such as 
corticotrophin-releasing factor and interleukin-6, which are not present in plasma from 
healthy controls, evokes larger calcium responses in enteric neurons38,39. However, blocking 
GHSR-1 did not alter calcium responses evoked by IBS plasma in SD submucosal or 
myenteric neurons. Indeed, ghrelin levels were not different between healthy controls and 
IBS patients, which is consistent with a previous study43. Interestingly, the amplitude of the 
response evoked by pooled IBS plasma in WKY submucosal, but not myenteric neurons, was 
reduced in the presence of a GHSR-1 antagonist. Submucosal neurons regulate GI absorpto-
secretory function, which is altered in WKY rats33,44. These findings may indicate a possible 
role for ghrelin in absorpto-secretory dysfunction in the WKY model of IBS. However, what 
is perhaps more interesting, is the capacity of MK-667 to modify the sensitivity of enteric 
neurons to the GLP-1R agonist, Ex-4.  
 
Some17,45, but not all studies46,47 show that ghrelin can stimulate L-cells to secrete GLP-1, or 
ghrelin may prime intestinal L-cells for nutrient-induced GLP-1 secretion17, fitting with the 
temporal peak in ghrelin concentrations prior to ingestion of a meal and subsequent GLP-1 
release18. In our experiments, only supra-physiological concentrations of Ex-4 evoked small, 
short-lived increases in intracellular calcium in both submucosal and myenteric neurons. This 
may reflect a mechanism where local L-cell activation facilitates the accumulation of higher 
concentrations of GLP-1 to activate enteric neurons through paracrine mechanisms. However, 
research demonstrating that feeding status tunes the sensitivity of myenteric neurons to 
orexigenic or anorexigenic molecules2,48, and our finding that GHSR-1 activation sensitizes 
enteric neurons to Ex-4, could explain how colonic neurons gain sensitivity to post-prandial 
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physiological concentrations of GLP-1. This increase in sensitivity is time-limited however as 
it is not apparent 30 minutes after exposure to MK-667. GLP-1 may also contribute to the 
neurostimulatory actions of IBS plasma in both neuronal plexi of both rat strains as the GLP-
1R antagonist resulted in a decrease in the amplitude of response. However, it is likely that 
GLP-1 is just one contributory factor in the altered modulation of enteric neurons, as we have 
previously noted the importance of immune factors and circulatory hormones in this 
effect38,39,49. In our cohort we found that fasting GLP-1 was lower in IBS-D with no change 
in IBS-C patients, which contrasts with a report that indicated plasma GLP-1 was decreased 
in IBS-C patient samples50.  
 
Others have examined the functional effects of GLP-1 on mucosal secretory physiology and 
postulated that activation of submucosal GLP-1Rs leads to a decrease in neurally evoked 
chloride secretion, a pathway mediated through suppression of neural acetylcholine4. Thus, 
we focused on colonic contractile activity. Striking differences in basal smooth muscle 
contractile activity were noted in SD and WKY rats, which is similar to differences in colonic 
contractility reported between WKY and SHR rat comparators51. Sustained colonic tone and 
regular circular muscle contractions in SD rats contrasted with an erratic baseline tone and 
contractile frequency observed in WKY colons. Basal activity in longitudinal smooth muscle 
also differed between strains and combined, this is likely to underlie dysfunctional GI transit 
in WKY rats32. In SD circular muscle, Ex-4 evoked a small increase in tone and contractions 
that were more frequent but of smaller amplitude. In WKY rats, the large amplitude erratic 
contractions, characteristic of basal contractile activity, was suppressed by Ex-4. In 
longitudinal muscle, Ex-4 caused suppression of colonic contractions and tone in SD rats, 
although regular contractile activity returned following washout. In WKY rats the inhibitory 
effects of Ex-4 on longitudinal muscle contractile function was reversed upon washout, 
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although the amplitude of contractions remained suppressed. The suppressive effects of Ex-4 
in WKY rat colons are consistent with reports that GLP-1 mimetics suppress intestinal 
motility in both humans6 and rats52, and this may underpin the therapeutic benefits of GLP-1 
mimetics in IBS.  
 
Prior exposure to the GHSR-1 agonist, which aimed to replicate the peak in ghrelin prior to 
food ingestion, modified the effect of Ex-4 in circular and longitudinal muscle in both rat 
strains, although the basal pattern of contraction in each strain influenced the outcome. While 
Ex-4 applied to naïve tissue made contractile responses more quiescent and caused a decrease 
in colonic tone, re-application of Ex-4 after MK-667 exposure caused an increase in colonic 
tone and larger, more frequent contractions. In health, increased contractile activity following 
food ingestion may be important in stimulating fecal transit in preparation for the arrival of 
more luminal content. However, in pathophysiological conditions, such as IBS this 
contractile activity may contribute to abdominal pain associated with contraction of hollow 
viscera, which are the most frequently reported symptoms exacerbated by food intake in 
IBS15. Consistent with the potentiating effects of MK-677 on Ex-4-evoked activation of 
myenteric neurons, tetrodotoxin inhibited Ex-4-evoked suppression of basal contractile 
activity in circular muscle but not longitudinal muscle in SD rats. Given that the sensitivity of 
myenteric neurons to Ex-4 is similar between SD and WKY rats, we would expect to see a 
similar outcome in the pre-clinical IBS model, however this does need to be experimentally 
verified.  
 
The physiological mechanisms by which ROSE-010, a GLP-1 analogue, inhibits acute 
abdominal pain in IBS12 and relieves constipation in IBS patients53, remain unclear. It may be 
via an endocrine pathway, however, given the short half-life of GLP-1 in plasma, direct 
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neural signaling is also likely to be important. Spinal afferents are important in pain 
signaling, and a recent paper demonstrated expression of GLP-1Rs in DRG neurons54. 
However, GLP-1 did not directly stimulate calcium responses in these neurons. Moreover, 
the nociceptive receptor, TRPV1 was not affected by acute application of GLP-1, leading the 
authors to conclude that pain signaling is perhaps not modulated via this pathway. The vagus 
has been implicated in the pathophysiology of IBS, as it can stimulate the stress 
hypothalamic-pituitary-adrenal axis, modulate the neuro-immune axis and pain signaling 
originating in the gut, contributing to bowel dysfunction23. The dorsal motor nucleus of the 
vagus is sensitive to GLP-125 and intravenous injection of GLP can stimulate vagal firing26. 
GLP-1Rs are expressed in the nodose ganglion55, where vagal afferent neurons innervating 
the abdominal viscera are found56. Thus, central regulation of visceral pain sensitivity could 
be influenced by GLP-1. Ex-4 increased the compound neural activity in vagal nerves when it 
was applied to myenteric neurons in the distal colon. Moreover, Ex-4-evoked vagal nerve 
activation was enhanced by prior exposure to the GHSR-1 agonist.  
 
The reported exaggeration of the sensory component of the gastro-colonic response57 and 
increased colo-rectal sensitivity to balloon distension58 following food ingestion in IBS could 
be due to modulation of peripheral neurons by orexigenic and anorexigenic hormones. This 
study has provided evidence to support a role for ghrelin, which is primarily described as a 
driver of feeding, in priming both colonic enteric neurons and vagal afferents originating in 
the colon for the neurostimulatory actions of GLP-1. GLP-1 is secreted upon arrival of food 
in the small intestine but also in response to luminal molecules such as microbial factors, bile 
acids and short-chain fatty acids, which are more abundant in the distal intestine. Our data 
suggest that ghrelin receptor activation sensitizes intrinsic and extrinsic gut neurons to GLP-1 
as part of the normal physiological response to the arrival of food in the gut. However, 
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underlying dysfunction of contractile activity or gut-brain signaling, as evident in the WKY 
rat model of IBS, may dictate whether the outcome is physiological or pathophysiological. 
Thus, the temporal regulation of ghrelin and GLP-1 may contribute to the post-prandial 
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Figure 1: Circulating GLP-1 is depressed in IBS-D samples. 
A: The box and whisker plots illustrate circulating plasma levels of (i) GLP-1 and (ii) ghrelin 
and (iii) supernatant concentration of GLP-1 in healthy controls (HCs), constipation- (IBS-C) 
or diarrhea (IBS-D) – predominant irritable bowel syndrome patient samples. B: The box and 
whisker plot and representative immunofluorescent images of GLP-1-expressing L-cells 
compare L-cell numbers in HC, IBS-C and IBS-D human colonic biopsies. Scalebar: 50µm. * 
indicates p<0.05. 
 
Figure 2: GLP-1 contributes to the neurostimulatory effects of IBS plasma. 
The box and whisker plots and representative calcium imaging traces illustrate the 
stimulatory effect of IBS plasma on A: Sprague Dawley (SD) and B: Wistar Kyoto (WKY) 
colonic submucosal (SMP) neurons. IBS plasma also stimulates myenteric (LMMP) neurons 
in C: SD and D: WKY rats. The calcium response in SMP and LMMP neurons is inhibited by 
the GLP-1 receptor antagonist, exendin (9-39) (Ex(9-39)) in both strains. The ghrelin receptor 
(GHSR-1) antagonist, YIL781 has no effect on SD SMP neurons or LMMP neurons in both 
strains, but does attenuate the response in WKY submucosal neurons. ** and *** indicate 
p<0.01 and p<0.001, respectively. 
 
Figure 3: MK-667 sensitizes submucosal neurons to Ex-4 in both Sprague Dawley and 
Wistar Kyoto colons. 
A: The box and whisker plots and sample calcium imaging traces illustrate the reproducibility 
of the calcium response evoked by Ex-4 in SD submucosal neurons. The change in 
fluorescence evoked by Ex-4 (10µM) was potentiated by exposure to MK-667 in both B: 
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Sprague Dawley and C: Wistar Kyoto rats. ** and *** indicate p<0.01 and p<0.001, 
respectively. 
 
Figure 4: MK-667 potentiates the Ex-4-evoked response in Sprague Dawley and Wistar 
Kyoto myenteric neurons.  
A: The box and whisker plots and sample calcium imaging traces illustrate the reproducible 
calcium response evoked by Ex-4 (10µM) in Sprague Dawley myenteric neurons. B: The 
change in fluorescence in myenteric neurons evoked by Ex-4 before and after exposure to the 
ghrelin receptor agonist, MK-667 (1µM) is shown in Sprague Dawley and C: Wistar Kyoto 
rats. ** and *** indicate p<0.01 and p<0.001, respectively. 
 
Figure 5: MK-667 potentiates Ex-4 evoked contractile activity in Sprague Dawley and 
Wistar Kyoto colons.  
The box and whisker plots and representative colonic contractile activity recordings illustrate 
how Ex-4 differentially modifies circular muscle contractility in A: Sprague Dawley and B: 
Wistar Kyoto rats. Following exposure to MK-667 the response to Ex-4 is potentiated. The 
box and whisker plots and colonic contractile activity traces illustrate the effect of Ex-4 on 
baseline contractile activity in longitudinal muscle in both C: Sprague Dawley and D: Wistar 
Kyoto rats. Application of Ex-4 following exposure to MK-667 resulted in a dramatic change 
in colonic tone in both Sprague Dawley and Wistar Kyoto rats and a potentiation of the 
contractile response. * indicates P<0.05. 
 
Figure 6: Vagal nerve activity evoked by Ex-4 application to myenteric neurons is 
enhanced by exposure to MK-667. 
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The box and whisker plots and representative un-filtered and filtered extracellular recordings 
from vagal nerves, recorded superior to the stomach, show that application of Ex-4 to colonic 
myenteric neurons stimulates afferent nerve firing in both A: Sprague Dawley and B: Wistar 
Kyoto rats. While MK-667 itself evokes a moderate stimulatory response, the capacity of Ex-
4 to evoke vagal nerve firing is enhanced following exposure to MK-667 in both strains of 
rat, although this effect is potentiated in the Wistar Kyoto rat. * indicates p<0.05. 
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